Shenzhen Microchip Biotechnology Co., Ltd., a developer of original small molecule drugs, is a high-tech enterprise mainly engaged in the technology research and development of innovative drugs with new chemical structures
Chipscreen Biosciences is a biotechnology high-tech enterprise founded by a senior team returning from studying in the United States, specializing in the research and development of original small molecule drugs. The original team and the local team have high scientific attainments in the field of biomedical research, practical experience in the R&D and management of innovative drugs, successful experience in establishing and managing enterprises in Europe and the United States, familiar with global drug management technical regulations and patent strategies, and familiar with the Chinese drug market.
The core technology that supports the company's sustainable development is our self-built integrated drug innovation and early evaluation technology system based on chemical genomics. This platform system effectively integrates a number of modern technologies including computer-aided drug design, drug and combination chemistry, high-throughput and high-content drug screening, chemical genomics gene expression profiling research, bioinformatics and cheminformatics data mining, etc., which can effectively accelerate the research and development process of small molecule innovative drugs and reduce the risk of new drug development.
Based on the law of international new drug research and development and the current situation of China's pharmaceutical market, Chipscreen Biosciences has explored a way to realize the benefits of enterprise development by granting patents to international pharmaceutical companies and establishing international clinical joint development while retaining the rights and interests of Chinese products. At the same time, we will establish a business model for high-level cooperative research with multinational pharmaceutical companies. Through this development strategy, Chipscreen Biosciences' innovative drugs under development can not only be marketed in China as soon as possible, but also achieve the goal of entering the global market for China's original drugs in the future through international clinical joint development. This innovative development model – profitable and growing through patent licensing, collaborative research and eventual product marketing – has changed the substantial flaw of the lack of original drugs in China's local pharmaceutical companies, and has created a precedent from "Chinese imitation" to "Chinese creation".
Since its establishment, Chipscreen Biosciences has made breakthroughs in new drug research and development, intellectual property rights, and business development around the establishment of a corporate development strategy with patents and innovative drugs as its core competitiveness, and has achieved the first place in many industries and fields, making positive contributions to China's innovative drug industry.
Chipscreen Biosciences has the complete ability from drug target research to clinical drug candidate development and industrialization, and has successfully cultivated a technology and management team specializing in the research and development of innovative drugs with new chemical structures that is rare in China, which has become the core advantage to ensure the development of innovative small molecule chemical drugs with independent intellectual property rights as the core, for major diseases, global patent protection and unique clinical effects, and the core advantage of the company.
